Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu

Richard G. Moore, M.D.

Contact Information

Phone Numbers

Appointment: (585) 442-8020

Office: (585) 442-8020

Fax: (585) 442-8039

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Cancer, Obstetrics & Gynecology

Biography

I believe all patients should be treated with compassion, along with an individualized plan for their treatment and care utilizing a multidisciplinary team approach. We approach each of our patients with the philosophy of "What would you want done for your loved one?" (Quote from Cornelius "Skip" Granai, III, M.D.)

Gynecologic oncology is a unique subspecialty that provides for the participation in all parts of a patient's care. The opportunity to be involved in such a personal experience during a patient's life -- from the time of diagnosis through surgery to managing chemotherapy and participating in all aspects of a woman's care -- is an honor and privilege.

My areas of expertise include robotic surgery for ovarian, endometrial and cervical malignancies, as well as sentinel lymph node mapping for endometrial, cervical and vulvar malignancies, and ovarian cancer biomarker research for the early detection and management of ovarian cancer.

Conditions I Treat:

- Ovarian cancer
- Fallopian tube cancer
- Primary peritoneal cancer
- Endometrial cancer
- Cervical cancer
- Vaginal cancer
- Vulvar cancer

Professional Background

Richard G. Moore, M.D., FACOG, FACS, joined UR Medicine's Obstetrics and Gynecology as the Director of the Gynecologic Oncology Division on October 1, 2015. Dr. Moore will also lead Wilmot Cancer Institute's Gynecology Service Line and serve as Director of the Targeted Therapeutics Laboratory for Gynecologic Cancers.

Dr. Moore comes to UR Medicine from Brown University and Women & Infants Hospital of Rhode Island. A native of Montreal, Quebec, Canada, Dr. Moore graduated from the University of Alberta Medical School in Edmonton. He completed his residency at Eastern Virginia Graduate School of Medicine, where he also served as Administrative Chief Resident. He completed a fellowship in Gynecologic Oncology and Breast Surgery at Women & Infants Hospital/Brown University. Dr. Moore joined the faculty at Women and Infants/Brown University after leaving fellowship. He served as the Associate Director of the Program in Women's Oncology since 2009 and was the Director of the Center for Biomarkers and Emerging Technology as well as the Molecular Therapeutics laboratory.
Dr. Moore is board-certified in gynecologic oncology and is a fellow of the American College of Obstetricians and Gynecologists and a fellow of the American College of Surgeons.
In addition to his clinical interest in ovarian and endometrial cancers, Dr. Moore is recognized internationally as a leading expert on the use of biomarkers to detect ovarian cancer. He led the team that developed the Risk of Ovarian Malignancy Algorithm (ROMA), a test that is cleared for use in Europe and Asia and was recently cleared by the U.S. Food and Drug Administration to detect ovarian cancer in women who have an ovarian cyst or pelvic mass.
Dr. Moore will see patients at 125 Lattimore Road, Suite 258 and will perform surgeries at Highland Hospital, which has been awarded the Gold Seal of Approval by the Joint Commission and leads the state in the number of minimally invasive, robotic surgeries for gynecologic cancer performed each year.

Credentials

Specialties

  • Gynecologic Oncology - American Board of Obstetrics and Gynecology
  • Obstetrics and Gynecology - American Board of Obstetrics and Gynecology

Education

1993
MD | University of Alberta

Post-doctoral Training & Residency

07/01/1999 - 06/30/2002
Fellowship in Gynecologic Oncology at Brown University Program in Medicine

07/01/1994 - 06/30/1997
Residency in Obstetrics and Gynecology at Eastern Virginia Medical School of the Medical Col

07/01/1993 - 06/30/1994
Internship in Obstetrics and Gynecology at Eastern Virginia Medical School of the Medical Col

VIEW ALL expand_more

Awards

2015
Consumer's Research Council of America
Sponsor: Guide to America's Top Obstetricians and Gynecologists

2014 - 2014
New England Association of Gynecologic Oncologists
Sponsor: Basic Science Paper Award. Mentee: Elizabeth Lokich, MD. HE4 ex
Location: Newport RI,

2014
Rhode Island Monthly Journal, 2014
Sponsor: Rhode Island Top Doc

2013
AACC's Outstanding Speaker Award for 2013
Sponsor: American Association of clinical Chemists

2013
Consumer's Research Council of America
Sponsor: Guide to America's Top Obstetricians and Gynecologists

2013
Rhode Island Monthly Journal, 2013
Sponsor: Rhode Island Top Doc

2012
Rhode Island Monthly Journal, 2012
Sponsor: Rhode Island Top Doc

2012
Consumer's Research Council of America
Sponsor: Guide to America's Top Obstetricians and Gynecologists

2011
Providence Business News Innovation Awards 2011
Sponsor: For the "Artificial Ovary
Location: Brown University and Women and Infants Hospital

2011
Consumer's Research Council of America
Sponsor: Guide to America's Top Obstetricians and Gynecologists

2010
Time Magazine: Top ten Medical Breakthroughs for 2010
Sponsor: In vitro maturation of oocytes via the prefabricated self-assem

2008
New England Association of Gynecologic Oncologists
Sponsor: Comparison of a novel multiple biomarker assay to the risk of ma
Location: Cape Cod

2008
New England Association of Gynecologic Oncologists
Sponsor: Differential expression of CA125 and a novel serum tumor marker
Location: Cape Cod

2008
Full Time Faculty Excellence in Teaching Award

2008
Teaching Award from Chief Residents: Full Time Faculty

2007 - 2007
SGO Clinical Practice Science Poster Award
Sponsor: sentinel lymph node dissection alone with conservative ...
Location: San Diego, CA

2006
Medical Student Teaching Award
Sponsor: BioMed 351
Location: Brown University

2006
2006 Outstanding faculty mentorship award; from the resident graduating class of 2006

2005
New England Association of Gynecologic Oncology
Sponsor: Long term follow-up of patients with stage I and II vulvar ...

2002
New England Association of Gynecologic Oncologists
Sponsor: Sentinel node identification and the ability to detect ...

1997
The American Association of Gynecologic Laparoscopists Award

1996 - 1997
Resident of the Year

1996 - 1997
Administrative Chief Resident

1996
Gynecologic Oncology Resident Award

1996
Society of Assisted Reproductive Medicine Award

VIEW ALL expand_more

Clinical Trials

Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin

Lead Researcher: Richard G Moore

This trial studies how well iohexol, a contrast agent, works in helping doctors calculate the dose of carboplatin given to patients with cancer. A contrast agent is a substance used to increase the contrast of structures or fluids within the body in medical imaging. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Understanding how to best calculate the dose of carboplatin given to patients with cancer may help doctors learn how to improve the use of carboplatin in the future.

View Study Details

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

Lead Researcher: Richard G Moore

This phase III trial studies how well the combination of pembrolizumab, paclitaxel, and carboplatin, works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III, IV, or has come back (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel and carboplatin are chemotherapy drugs used as part of the usual treatment approach for this type of cancer. This study aims to assess if adding immunotherapy to these drugs is better or worse than the usual approach for treatment of this cancer.

View Study Details

NRG-GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Lead Researcher: Richard G Moore

This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving letrozole alone or in combination with paclitaxel and carboplatin works better in treating patients with low-grade serous carcinoma of the ovary or peritoneum compared to paclitaxel and carboplatin without letrozole.

View Study Details

NRG-GY007: A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Lead Researcher: Richard G Moore

This phase I/II partially randomized trial studies the side effects and the best dose of ruxolitinib phosphate when given together with paclitaxel and carboplatin, and it will look at how well these drugs work in treating patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ruxolitinib phosphate together with paclitaxel and carboplatin may be a better treatment for epithelial ovarian, fallopian tube, or primary peritoneal cancer.

View Study Details

NRG-GY014: A Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endemetrial Adenocarcinoma

Lead Researcher: Richard G Moore

This phase II trial studies how well tazemetostat works in treating patients with ovarian, primary peritoneal, or endometrial cancer that has come back. Drugs used in chemotherapy, such as tazemetostat, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

View Study Details

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women With Recurrent, Persistent or Metastatic Endometrial Cancer (NRG-GY012)

Lead Researcher: Richard G Moore

This phase II trial studies how well olaparib and cediranib maleate work in treating patients with endometrial cancer that has come back (recurrent), does not respond to treatment (refractory), or has spread to other places in the body (metastatic). Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

View Study Details

A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (MK7902-001)

Lead Researcher: Richard G Moore

This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial (uterine) cancer. Participants will be randomly assigned to receive either pembrolizumab and lenvatinib or treatment of physician's choice. The primary study hypothesis is that pembrolizumab in combination with lenvatinib prolongs progression free survival (PFS) and overall survival (OS) when compared to treatment of physician's choice.

View Study Details

IGYE18025: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with Advanced Endometrial Cancer

Lead Researcher: Richard G Moore

If you decide to participate in this study, you will be assigned by chance to get either lenvatinib plus pembrolizumab or doxorubicin or paclitaxel. You will know what treatment you will be assigned to receive.

View Study Details

UGYO18036: Utilizing Human Ovarian, Fallopian and Primary Peritoneal Cancer Patient Tissue to Identify Novel Therapies

Lead Researcher: Richard G Moore

If you decide to take part in this study, you will be asked to donate tissue and ascites (left over after the surgery), blood and clinical data. Our study team member will first review your medical records to obtain information on your health status and history. Then, when you go in for surgery, on the day of surgery less than 4 tablespoons of blood and tissue samples and ascites fluid will be collected. You will be followed for information about your health status and treatment for up to 10 years after your surgery.

View Study Details

IGYO18026: A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Niraparib Combined with Bevacizumab as Maintenance Treatment in Patients with Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab

Lead Researcher: Richard G Moore

It is not known how long your participation the study will last. You may receive Niraparib for up to 3 years and Bevacizumab for up to 15 months. The number of months that you receive bevacizumab on the study depends on how many months of bevacizumab you received with chemotherapy before this study.

View Study Details

A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer (NRG-GY006)

Lead Researcher: Richard G Moore

This randomized phase III trial studies radiation therapy and cisplatin with triapine to see how well they work compared to the standard radiation therapy and cisplatin alone in treating patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA vaginal cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy and cisplatin are more effective with triapine in treating cervical or vaginal cancer.

View Study Details

IGYO-16111 A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation,IGYO-16111 A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Lead Researcher: Richard G Moore

The purpose of the study is to see if the combination of two drugs, cediranib and olaparib, is effective and tolerable in patients with ovarian cancer who have received at least 3 prior chemotherapy treatments, including treatment that included either carboplatin or cisplatin, and their disease came back within 6 months of the last dose of chemotherapy that included either cisplatin or carboplatin.

View Study Details

CGYO18021: Testing the addition of the antibody, atezolizumab, to chemotherapy with liposomal doxorubicin and bevacizumab in recurrent ovarian cancer

Lead Researcher: Richard G Moore

This study has 3 study groups, a computer will assign you to a study group by chance. There is an equal chance of receiving each treatment. This is done by chance, because no one knows if one study group is better or worse than the others. Group 1 will get an experimental chemotherapy treatment (liposomal doxorubicin and atezolizumab), group 2 will get an experimental chemotherapy treatment (liposomal doxorubicin and bevacizumab plus atezolizumab), and group 3 will get a usual chemotherapy treatment for this type of cancer (liposomal doxorubicin and bevacizumab). The liposomal doxorubicin will be given into your vein over approximately 60 minutes. The bevacizumab will be given into your vein over approximately 90 minutes initially, then faster at later visits if administration goes smoothly at the slower rates. The atezolizumab will be given into your vein over approximately 60 minutes initially, then faster at later visits if administration goes smoothly at the slower rates. Treatment will be given on days 1 and 15 of each 28-day period. This period of time is called a cycle, which is a regular schedule of treatment with periods of rest in between.

View Study Details

GOG 0263: RANDOMIZED PHASE III CLINICAL TRIAL OF ADJUVANT RADIATION VERSUS CHEMORADIATION IN INTERMEDIATE RISK, STAGE I/IIA CERVICAL CANCER TREATED WITH INITIAL RADICAL HYSTERECTOMY AND PELVIC LYMPHADENECTOMY.

Lead Researcher: Richard G Moore

You will get either standard treatment with radiation therapy OR standard treatment with radiation therapy with the addition of cisplatin chemotherapy.

View Study Details

UGYO17017: Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

Lead Researcher: Richard G Moore

You will have blood drawn for the CA-125 testing and other tumor markers, depending on your CA-125 level, you will return and have blood drawn in 1 year or in 3 months or in 6 weeks plus a transvaginal ultrasound.

View Study Details

Patents

Patent Title: Therapy for Malignant Disease
Patent #: 10,376,535
Issue Date: Aug 13, 2019
Country: United States
Invented By: Richard G Moore, Rakesh K Singh, Naohiro Yano

Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: 9,982,010
Issue Date: May 29, 2018
Country: United States
Invented By: Richard G Moore, Rakesh K Singh

Patent Title: 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: 10,683,324
Issue Date: Jun 16, 2020
Country: United States
Invented By: Richard G Moore, Rakesh K Singh

VIEW ALL expand_more

Publications

Journal Articles

5/22/2020
James NE, Emerson JB, Borgstadt AD, Beffa L, Oliver MT, Hovanesian V, Urh A, Singh RK, Rowswell-Turner R, DiSilvestro PA, Ou J, Moore RG, Ribeiro JR. "The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes." Scientific reports.. 2020 May 22; 10(1):8558. Epub 2020 May 22.

2/24/2020
Kim KK, Singh RK, Khazan N, Kodza A, Singh NA, Jones A, Sivagnanalingam U, Towner M, Itamochi H, Turner R, Moore RG. "Development of Potent Forchlorfenuron Analogs and Their Cytotoxic Effect in Cancer Cell Lines." Scientific reports.. 2020 Feb 24; 10(1):3241. Epub 2020 Feb 24.

2020
Kim KK, Turner R, Khazan N, Kodza A, Jones A, Singh RK, Moore RG. "Role of trypsin and protease-activated receptor-2 in ovarian cancer." PloS one.. 2020 15(5):e0232253. Epub 2020 May 04.

Books & Chapters

2011
Chapter Title: Breast Development and Anatomy
Book Title: Clinical Obstetrics and Gynecology
Author List: Sonali Pandya and Richard G. Moore
Published By: Wolters Kluwer / Lippincott Williams & Wilkins 2011

2011
Chapter Title: Management of Ovarian Cysts and Adnexal Masses
Book Title: Precis Gynecology
Author List: Richard G. Moore and Shannon MacLaughlan
Published By: Precis: Gynecology 2011

2011
Chapter Title: Forward
Book Title: Clinical Obstetrics and Gynecology,
Author List: James W. Orr and Richard G. Moore
Published By: Wolters Kluwer / Lippincott Williams & Wilkins 2011

VIEW ALL PUBLICATIONS